Catheter Precision Announces Strategic Sale of Non-Core Assets to Strengthen Balance Sheet and Accelerate Electrophysiology Growth

Rhea-AI Summary

Catheter Precision (NYSE American: VTAK) announced a definitive agreement to sell its atherectomy catheter technologies, including associated FDA approvals and patents, to a strategic acquirer on Feb 19, 2026.

Transaction delivers an upfront cash payment of $15,000, a 5% equity stake in the buyer with anti-dilution protection tied to up to $5 million additional equity, and a 10-year royalty on net sales starting at 1.5% and rising to 3% for quarters above $5 million. Company says proceeds will strengthen the balance sheet and sharpen focus on electrophysiology growth.

Positive

• 5% equity stake in acquirer provides potential upside
• 10-year royalty stream of 1.5%–3% on net sales
• Balance sheet strengthened and capital reallocated to electrophysiology

Negative

• Upfront cash infusion is only $15,000
• Sale transfers FDA approvals and patents away from the company
• Near-term revenue from divested atherectomy products will cease

News Market Reaction – VTAK

-6.47%

10 alerts

-6.47% News Effect

+7.5% Peak Tracked

-21.8% Trough Tracked

-$196K Valuation Impact

$3M Market Cap

0.3x Rel. Volume

On the day this news was published, VTAK declined 6.47%, reflecting a notable negative market reaction. Argus tracked a peak move of +7.5% during that session. Argus tracked a trough of -21.8% from its starting point during tracking. Our momentum scanner triggered 10 alerts that day, indicating notable trading interest and price volatility. This price movement removed approximately $196K from the company's valuation, bringing the market cap to $3M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Upfront cash payment: $15,000 Equity stake: 5% Anti-dilution protection: $5 million +4 more

7 metrics

Upfront cash payment $15,000 Cash received at closing for atherectomy catheter divestiture

Equity stake 5% Equity ownership in acquiring company with anti-dilution protection

Anti-dilution protection $5 million Protection up to $5M of additional equity capital in acquiring company

Royalty term 10 years Duration of royalty payments on divested atherectomy technologies

Baseline royalty rate 1.5% Royalty on net sales of divested technologies

Tiered royalty rate 3% Royalty on quarterly net sales above $5 million

Royalty threshold $5 million Quarterly net sales level triggering 3% royalty rate

Market Reality Check

Price: $1.37 Vol: Volume 53,913 is below 20...

low vol

$1.37 Last Close

Volume Volume 53,913 is below 20-day average 167,561 (relative volume 0.32). low

Technical Price $1.70 is trading below 200-day MA of $3.13, reflecting a longer-term downtrend.

Peers on Argus

VTAK was up 6.25% while 3 tracked peers in momentum (BJDX, NUWE, BMRA) were movi...

1 Up 3 Down

VTAK was up 6.25% while 3 tracked peers in momentum (BJDX, NUWE, BMRA) were moving down (median about -3.5%), and only BBLG was up modestly. This divergence points to a VTAK-specific reaction to the asset sale news rather than a broad medical devices move.

Historical Context

5 past events · Latest: Feb 17 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 17	Strategic equity stake	Positive	+11.9%	Acquisition of 19.98% stake in AI-enabled regional aviation operator Fly Flyte.
Feb 12	Strategic financing	Positive	-33.2%	Up to $36.5M institutional financing and liability conversion to strengthen liquidity.
Feb 05	Product conference feature	Positive	-4.8%	LockeT device featured in live cases at structural heart intervention conference.
Feb 04	Adoption momentum	Positive	+1.6%	Expanded hospital evaluations and approvals, record January revenue for LockeT.
Jan 22	International expansion	Positive	+10.4%	First LockeT purchase order in Germany and reference-site designation in Frankfurt.

Pattern Detected

Recent VTAK news has produced mixed reactions: strategic and product updates often saw positive moves, while complex financings and balance-sheet actions sometimes aligned with negative price reactions.

Recent Company History

Over the past month, VTAK announced multiple balance-sheet and strategic steps along with product traction for its LockeT device. On Jan 22, its first LockeT order in Germany saw a 10.45% gain. Subsequent adoption and conference visibility news brought smaller moves. A complex private placement and, later, up to $36.5M in strategic financing coincided with sharp volatility, including a -33.16% reaction. The Feb 17 aviation stake news drew an 11.89% rise. Today’s non-core asset sale continues the refocus and balance-sheet theme.

Market Pulse Summary

The stock moved -6.5% in the session following this news. A negative reaction despite this asset-sal...

Analysis

The stock moved -6.5% in the session following this news. A negative reaction despite this asset-sale structure would have fit VTAK’s pattern of volatility around balance-sheet events, such as the prior financing that coincided with a -33.16% move. While the transaction adds a $15,000 cash payment, a 5% equity stake, and tiered royalties up to 3%, investors might have focused on execution risk or the modest near-term cash component. The stock’s position below its $3.13 200-day MA could have amplified downside sentiment.

Key Terms

atherectomy catheter, fda approvals, anti-dilution protection, royalty payments, +1 more

5 terms

atherectomy catheter medical

"to divest its atherectomy catheter technologies, including associated FDA approvals"

Atherectomy catheter is a medical device used during minimally invasive procedures to remove plaque and blockages from inside blood vessels, functioning like a tiny rotary or suction tool threaded through the artery to clear the pathway. Investors care because its safety, effectiveness, regulatory approvals, and reimbursement determine how widely hospitals adopt it, which directly affects sales, recurring procedure volumes, and long-term revenue potential for device makers.

fda approvals regulatory

"atherectomy catheter technologies, including associated FDA approvals and patents"

FDA approvals are formal permissions granted by the U.S. Food and Drug Administration allowing a drug, medical device, or related product to be marketed and sold for a specific use after safety and effectiveness have been evaluated. For investors, an FDA approval is like a green light that can unlock sales, reduce regulatory uncertainty, and increase a product’s commercial value, while also signaling lower near-term regulatory risk compared with unapproved alternatives.

anti-dilution protection financial

"A 5% equity stake in the acquiring company with anti-dilution protection up to $5 million"

A contract feature that prevents an investor’s ownership percentage from shrinking when a company issues new shares, by automatically adjusting how many shares the investor holds or the price at which their special shares convert into common stock. It matters because it protects the value, voting power and potential future gains of early or preferred investors—like giving extra slices of a pie when the pie gets bigger so your piece stays the same size.

royalty payments financial

"Ten-year royalty payments agreement on net sales: 1.5% baseline"

Payments made to the owner of an asset, patent, trademark, mineral right, or creative work in exchange for permission to use it; they are typically a percentage of sales or a fixed fee per unit sold. For investors, royalty payments represent a steady income stream tied to the underlying product’s sales performance, similar to collecting rent from tenants — predictable cash flow that can reduce risk or add value when evaluating a company’s revenue sources.

net sales financial

"Ten-year royalty payments agreement on net sales: 1.5% baseline"

Net sales is the total money a company earns from selling its goods or services after subtracting returns, discounts, and allowances — like a store counting the cash it actually keeps after refunds and coupons. Investors use net sales to gauge true customer demand and the real size of a business’s revenue stream, since it forms the basis for profit margins, growth trends, and comparisons between companies.

AI-generated analysis. Not financial advice.

Upfront Cash, Equity Participation and Tiered Royalty Structure Providing Long-Term Revenue Upside

FORT MILL, S.C., Feb. 19, 2026 (GLOBE NEWSWIRE) --  Catheter Precision, Inc. (NYSE American: VTAK), a leader in advanced electrophysiology solutions, today announced it has entered into a definitive agreement to divest its atherectomy catheter technologies, including associated FDA approvals and patents, to a strategic acquirer.

Following a comprehensive portfolio review, the Company determined that monetizing these non-core assets enhances capital efficiency and sharpens focus on its high-growth electrophysiology platform.

Strategic Rationale

• Focus our capital allocation on core cardiac arrhythmia technologies
• Strengthened balance sheet
• Simplified operating structure with enhanced strategic clarity
  
  

Transaction Highlights

• Upfront cash payment following closing of $15,000
• A 5% equity stake in the acquiring company with anti-dilution protection up to $5 million of additional equity capital being invested in the acquiring company
• Ten-year royalty payments agreement on net sales:
  • 1.5% baseline
  • Increases to 3% on quarterly net sales above $5 million
    
    

Value Creation Framework

• Small cash infusion
• Potential long-term equity upside participation
• Recurring revenue potential through performance-based royalties
  
  

Management believes the transaction positions the Company to accelerate execution across its electrophysiology product portfolio while maintaining exposure to future commercial success of the divested technologies.

About Catheter Precision

Catheter Precision is a U.S.-based medical device company advancing the treatment of cardiac arrhythmias through differentiated electrophysiology technologies developed in collaboration with leading physicians.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements preceded by, followed by or that otherwise include the words “believe,” “anticipate,” “estimate,” “expect,” “intend,” “plan,” “potential,” “project,” “prospects,” “outlook,” and similar words or expressions, or future or conditional verbs, such as “will,” “should,” “lends,” “would,” “may,” and “could,” are generally forward-looking in nature and not historical facts, including, without limitation, the potential long-term equity upside participation in the acquiring company, the potential of recurring revenue through performance-based royalties and our management’s belief that the transaction positions the Company to accelerate execution across its electrophysiology product portfolio while maintaining exposure to future commercial success of the divested technologies. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the Company's actual results, performance, or achievements to be materially different from any anticipated results, performance, or achievements for many reasons. Unless otherwise required by law, the Company disclaims any intention to, and undertakes no obligation to, revise any forward-looking statements, whether as a result of new information, a future event, or otherwise and such statements are made only as of the date hereof. For additional risks and uncertainties that could impact the Company's forward-looking statements, please see the Company's Form 10-K and Form 10-Q’s, including but not limited to the discussion under “Risk Factors” therein, which the Company has filed with the SEC and which may be viewed at www.sec.gov.

CONTACTS:
Investor Relations
973-691-2000
IR@catheterprecision.com

# # #

FAQ

What did Catheter Precision (VTAK) announce on February 19, 2026 regarding atherectomy assets?

Catheter Precision announced a definitive sale of its atherectomy catheter technologies to a strategic acquirer. According to the company, the deal includes FDA approvals, patents, upfront cash, equity participation, and a tiered royalty agreement.

How much immediate cash did VTAK receive from the asset sale announced Feb 19, 2026?

The transaction includes an upfront cash payment of $15,000 following closing. According to the company, this is complemented by equity participation and a performance-based royalty structure for long-term upside.

What equity and royalty terms did Catheter Precision (VTAK) secure in the divestiture?

VTAK receives a 5% equity stake in the acquiring company plus anti-dilution protection and a ten-year royalty. According to the company, royalties start at 1.5% and rise to 3% on quarterly net sales above $5 million.

How will the sale affect Catheter Precision's strategic focus and balance sheet (VTAK)?

The company said proceeds will sharpen focus on its electrophysiology platform and strengthen the balance sheet. According to the company, the move reallocates capital toward core cardiac arrhythmia technologies.

Does the VTAK transaction provide recurring revenue after the Feb 19, 2026 sale?

Yes; the deal includes a ten-year royalty agreement that can create recurring revenue based on acquirer sales. According to the company, the tiered royalty ranges from 1.5% up to 3% on higher quarterly sales.